Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SomaLogic Inc.

www.somalogic.com

Latest From Diagnostica Stago

European IVD Companies See Worrying Trend In Market Access Barriers

Are medtech regulators and authorities in wider Europe – including Russia – setting market access barriers too high, risking investment in innovation and potentially denying patients access to modern care? European Diagnostic Manufacturers Association (EDMA) representative Christian Parry fears so, in this second half of our industry update from the 2015 European MedTech Forum.

Medical Device Europe

FDA Guidance Sought To Fill Anticoagulant IVD Gap

There is a need for assays to help guide therapy with the growing number of anticoagulant drugs on the market, but without clearer FDA guidelines development will be a challenge, companies and labs tell the agency.

Medical Device Regulation

Deals Shaping The Medical Industry, July-August 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010

Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: With most of the funding in the form of venture rounds, medical device financing totaled $548 million in the second quarter, a 10% drop from Q1. Device acquisitions picked up, with 18 transactions completed for an aggregate $4.4 billion. Including GenMark's IPO, the first done in the sector since November 2007, in vitro diagnostic/research financing more than doubled Q1's dollar volume, reaching $364 million in the second quarter. The four IVD/Research acquisitions done in Q2 totalled $226 million.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SomaLogic Inc.
  • Senior Management
  • Bryon Hewett, CEO
    Dan Muehl, CFO
    Nebojsa Janjic, PhD, CSO
    Mark Messenbaugh, Exec. Dir., Corp. Strategy & Dev.
    Evan King, Exec. Dir., Bus. Operations
  • Contact Info
  • SomaLogic Inc.
    Phone: (303) 625-9000
    2945 Wilderness Pl.
    Boulder, CO 80301
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register